专利号:US-7420052-B2 优先权日:2001-08-24 标 题:Intermediates for synthesis of vinblastine, process for preparation of the intermediates and process for synthesis of vinblastines 发明人:FUKUYAMA TOHRU; TOKUYAMA HIDETOSHI; YOKOSHIMA SATOSHI 权利人:JAPAN SCIENCE & TECH AGENCY 摘要:An intermediate for vinblastine synthesis represented by general formula A. n ngeneral formula A.n n(in the formula, R 1 , R 2 , R 3 and R 4 are the group selected independently from the group consisting of H, lower alkyl group, lower alkoxy group, halogen, lower perfluoroalkyl group, lower alkylthio group, hydroxy group, amino group, mono- or di-alkyl or acylamino group, lower alkyl or arylsulfonyloxy group. R 5 is H, or a lower alkyl group or a substituted or non-substituted aryl group, R 6 is an alkyl group of carbon number 4 or less, R 7 is a substituted or non-substituted aryl group, R 8 is a substituted or non-substituted aryl group or lower alkyl group and R 9 is an acyl group or trialkylsilyl group.) A method for synthesis of the compound of general formula A utilizing radical ring forming reaction of thioanilides and using the compound of general formula B as the starting material, synthesizing thioanilide of general formula C by the reaction with compound 1 and the formation of a 11-membered ring by intramolecular alkylation of 2-nitrobenzenesulfonamide by which the reactions can proceed under mild conditions and high yield can be accomplished.
专利号:US-12383499-B2 优先权日:2018-01-01 标题:Scale up synthesis of silicasome nanocarriers 发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG 权利人:UNIV CALIFORNIA 摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).
专利号:US-4841045-A 优先权日:1985-03-12 标 题 :Synthesis of vinblastine and vincristine type compounds 发明人:KUEHNE MARTIN 权利人:UNIV VERMONT 摘要:A new process for the stereospecific synthesis of alkaloids of the vinblastine and vincristine type including the synthesis of vinblastine and vincristine as well novel alkaloids which are active as anti-tumor agents.
专利号:US-4897477-A 优先权日:1985-03-12 标题:Synthesis of vinblastine and vincristine type compounds 发明人:KUEHNE MARTIN 权利人:UNIV VERMONT 摘要:A new process for the stereospecific synthesis of alkaloids of the vinblastine and vincristine type including the synthesis of vinblastine and vincristine as well novel alkaloids which are active as anti-tumor agents.
专利号:US-RE37449-E 优先权日:1987-02-06 标题:Process of synthesis of 3′,4′-anhydrovinblastine, vinblastine and vincristine 发明人:KUTNEY JAMES P; CHOI LEWIS S L; NAKANO JUN; TSUKAMOTO HIROKI; BOULET CAMILLE A; MCHUGH MICHAEL 权利人:UNIV BRITISH COLUMBIA 摘要:The present invention relates to the synthesis of dimer alkaloid compounds, particularly those of the Catharantus (Vinca) family, from an indole unit, such as cantharanthine, and a dihydroindole unit, such as vindoline. A multi-step process is disclosed including the steps of (1) of 1,4-reduction of a first dimeric iminium intermediate to an enamine compound by reaction with a 1,4-dihydropyridine compound; (2) oxidative transformation of the resulting enamine to a second iminium intermediate under controlled aeration; (3) reduction of the second iminium intermediate to form the target dimer alkaloid compounds. The entire process can be conducted in a one-pot operation to obtain the target compounds without isolation of the intermediates.
专利号:US-6818777-B2 优先权日:2000-12-07 标 题:Intermediates for synthesis of vinblastine compound and method for synthesizing the intermediate 发明人:FUKUYAMA TOHRU; TOKUYAMA HIDETOSHI 权利人:JAPAN SCIENCE & TECH AGENCY 摘要:Intermediates A, which are important in the whole synthesis of vindoline; and a method of synthesizing intermediates respectively represented by the general formulae B and C. By the method, the target intermediates are effectively synthesized with satisfactory reproducibility. This synthesis method is especially suitable for mass production. General formula A General formula B General formula C.
1: Lee HJ, Ramchandren R, Friedman J, Melear J, Flinn IW, Burke JM, Linhares Y, Gonzales P, Peterson M, Raval M, Chintapatla R, Feldman TA, Yimer H, Islas- Ohlmayer M, Patel A, Metheny L, Dean A, Rana V, Gandhi MD, Renshaw J, Ho L, Fanale MA, Guo W, Yasenchak CA. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16;145(3):290-299. doi: 10.1182/blood.2024024681. 46 Suppl 6(Suppl 6):S250-S256. doi: 10.1016/j.htct.2024.07.007. Epub 2024 Sep 25. 3: Dulley LH, Braga AGO, Rodrigues GG, Fortier SC, Chiattone CS, da Silveira TMB. Lower doses of dacarbazine (modified BEACODD) as a safer strategy with equal effectiveness in an intensive treatment protocol of Hodgkin's lymphoma: a preliminary retrospective analysis of a single public center in Brazil. Hematol Transfus Cell Ther. 2024 Sep 7:S2531-1379(24)00306-7. doi: 10.1016/j.htct.2024.06.003. Epub ahead of print. 53(11):5089-5104. doi: 10.1039/d3dt04024k.
合成参考文献
摘要:Cancer Research., 39(3575), 1979 [] 参考文献:10.1007/bf00286057 摘要:Buys CH, Stienstra S. Involvement of sulfhydryl groups of chromosomal proteins in sister chromatid differentiation. Chromosoma. 1980;77(3):325–32. doi: 10.1007/bf00286057. 参考文献:10.2165/00003088-199631030-00003 摘要:Levêque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet. 1996 Sep;31(3):184–97. doi: 10.2165/00003088-199631030-00003. 参考文献:10.1007/s00280-001-0411-5 摘要:Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother Pharmacol. 2002 May;49(5):391–7. doi: 10.1007/s00280-001-0411-5. 参考文献:10.1007/978-1-59745-033-1_20 摘要:Ford LP, Cheng A. Using synthetic precursor and inhibitor miRNAs to understand miRNA function. Methods Mol Biol. 2008;419():289–301. doi: 10.1007/978-1-59745-033-1_20.